Matar S, Skah S, Diomande LE, Buss T, Hagland HR, Yadav A, Forstrøm RJ, Dalhus B, Hestdal K, Pettersen RD, Richartz N(2025) Development of a novel bifunctional anti-CD47 fusion protein with improved efficacy and a favorable safety profile Mol Cancer Ther(in press) DOI 10.1158/1535-7163.MCT-24-0917, PubMed 40084615
Mester S, Chan C, Lustig M, Foss S, Jansen JHM, Leangen Herigstad M, Evers M, Nilsen J, Reiding KR, A Damen JM, Burger R, Grevys A, Dalhus B, Valerius T, Sandlie I, Leusen JHW, Andersen JT(2025) Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life PNAS Nexus, 4(2), pgaf042 DOI 10.1093/pnasnexus/pgaf042, PubMed 40041621
Misceo D, Lirussi L, Strømme P, Sumathipala D, Guerin A, Wolf NI, Server A, Stensland M, Dalhus B, Tolun A, Kroes HY, Nyman TA, Nilsen HL, Frengen E(2023) A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis Brain, 146(8), 3513-3527 DOI 10.1093/brain/awad086, PubMed 36917474
Contact information: Group leader Bjørn Dalhus, research scientist, Dr. scient. Department of Microbiology & Department of Medical Biochemstry Oslo University Hospital Rikshospitalet PO Box 4950 Nydalen NO-0424 Oslo, Norway Tel: +47 23070809 Fax: +47 23074061 E-mail: bjorn-dalhus@medisin.uio.no
